Author Archives: Bruno Quinney

#Clinical trial #Immunic Therapeutics #MS #Multiple sclerosis

Immunic appoints Erik Lundgren as CEO 

Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer.  Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases.  Lundgren recently served… Read More

#News

Heart
#AAV #Circio Holding #Gene therapy #Heart disease

Circio and AaviGen collaborate on heart disease gene therapy 

Biotechnology companies Circio Holding and AaviGen have announced a research collaboration to develop heart disease gene therapies.  The agreement will see the companies work to develop circVec-enhanced AAV vectors specifically engineered for targeted, low dose heart gene therapy.   The collaboration focus will be on addressing genetic… Read More

#News

AI clinical trials concept
#AI #Clinical trial #Pistoia Alliance

Trust and regulation holding back AI in clinical trials 

The use of AI in clinical trials is being held back by a lack of trust and regulatory uncertainty, professionals say.  A poll from The Pistoia Alliance found that half of respondents agreed trust and regulatory uncertainty were barriers to AI adoption in clinical trials. … Read More

#News

#COPD #National Institute for Health and Care Excellence (NICE) #NHS

NICE recommends mepolizumab as COPD add-on treatment 

The National Institute for Health and Care Excellence (NICE) has recommended Nucala (mepolizumab) as an add-on treatment for NHS patients with COPD.  The draft final guidance recommends mepolizumab as an add-on maintenance treatment option for adult patients with uncontrolled COPD with raised blood eosinophils, if they are having a triple therapy… Read More

#News #Regulatory

A strip of 8 PCR tubes on the thermal cycler
#Investment #PCR

Countable Labs raises $26m to commercialise PCR technology 

Countable Labs has said it has raised $26 million to accelerate its clinical product development and the global commercialisation of Countable PCR.  The biotechnology company raised the capital in an oversubscribed financing round, which will allow it to leverage capabilities to support cell and gene therapy, minimal residual… Read More

#News

Human brain
#Cancer research #Gene therapy #Trogenix

First patient dosed in glioblastoma gene therapy trial 

The first patient has been dosed in the Phase I/II clinical trial of a gene therapy for glioblastoma (GBM).  TGX-007, developed by oncology company Trogenix, is a dual-payload adeno-associated virus (AAV)-based gene therapy.   TGX-007 harnesses Trogenix’s proprietary Synthetic Super-Enhancer (SSE) technology to exploit the core cancer cell identity. The… Read More

#Cancer Research #News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

#Affibody #Breast cancer #Radioligand Therapies (RLTs)

Affibody to reveal data from first-in-human cancer trial 

First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced.  Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will… Read More

#Cancer Research #News

Kidneys
#Clinical trial #EMA #Hansa Biopharma #Transplant

Hansa Biopharma reports positive PAES results from Idefirix 

Hansa Biopharma has announced positive topline results from a study investigating Idefirix (imlifidase) in patients who have undergone HLA-incompatible kidney transplantation.  The biopharmaceutical company announced the primary objective of the post-authorisation efficacy study (PAES) was met, with 90% of highly sensitised kidney transplant patients achieving one‑year graft failure‑free survival – following Idefirix pre‑treatment to convert… Read More

#News

#Equity finance #Investment #Neuroscience

MindMaze Therapeutics raises CHF 8m in equity financing 

Neurotherapeutics company MindMaze Therapeutics has announced it has raised CHF 8 million (€8.7 million) in strategic equity financing.  The financing has been raised through a definitive agreement with Neuro.io, which will acquire a strategic equity position in the company.  MindMaze Therapeutics says it will use the funds raised to support… Read More

#News

#AI #Collaborative Drug Discovery (CDD) #Eli Lilly

CDD to make Eli Lilly models available in CDD Vault 

Collaborative Drug Discovery (CDD) has announced an agreement with Eli Lilly to make Lilly’s AI/ML models available in CDD Vault.  The models will come from Lilly TuneLab, the platform created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly’s… Read More

#News

#AI / data analytics / healthtech / informatics #EMA #FDA #Regulatory

Why pharma must refocus its data efforts if it really wants to exploit AI

Now that this industry is seriously looking to advanced automation to reinvent the work it does, the data transformation imperative has soared back up the strategic agenda, says Ian Crone, ArisGlobal’s VP Europe & APAC Regulatory Solutions. Here, he reports on an impassioned panel debate that took place as part of the Life Science AI Exchange Podcast last year. The panel included subject… Read More

#Exclusive Content #Opinion

Scientist using a laptop
#Biotech #CDMO #Clinical trial

Biotech reliance on large CDMOs could cause overruns of 40% 

Overreliance of biotechs on large CDMOs could cause overruns of up to 40%, an industry expert has warned.  Madhav Bhutada, Director of Shilpa Biologicals, urged biotechs to take a broader and earlier approach to CDMO selection as funding conditions improve across the sector.   Bhutada said many emerging biopharma innovators –… Read More

#News

Human liver
#Clinical trial #Liver disease #University of Edinburgh

Research suggests RMT could treat end-stage liver disease 

A pioneering Regenerative Macrophage Therapy (RMT) could represent a new method of treating end-stage liver disease, research shows.  Results from the University of Edinburgh’s MATCH trial, published in Cell Stem Cell, demonstrate RMT provides significantly prolonged transplant‑free survival after four years compared with those who received standard care. Read More

#News

Peptide
#Alzheimer's #Dementia #Peptides

Peptide ‘shuttles’ could transform Alzheimer’s treatment 

Research into the use of peptide ‘shuttles’ has been praised for its potential to overcome barriers in Alzheimer’s and dementia treatment.  Peter Davies, Deputy Director at the Texas A&M Health Institute of Biosciences and Technology, and his colleagues have been awarded a Dementia and Alzheimer’s Initiative (DARI)… Read More

#Editor's Choice #News

Colorectal cancer
#Cancer research #Colorectal cancer #Genetic profiling

Genetic pattern key to colorectal cancer, research shows 

A genetic pattern could explain how colorectal cancer develops, new research suggests.  Findings from ChristianaCare’s Helen F Graham Cancer Center & Research Institute identified a developmental genetic pattern that helps explain how colorectal cancer develops, why it becomes aggressive and how long patients are likely to survive.  The study, published… Read More

#Cancer Research #News